Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 17/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2880549 | 1.00 | GLP1R (0.41) | GLP1RKCNH2MCHR1HTR1ADRD2 | |
| SCHEMBL2884090 | 0.90 | MCHR1 (0.43) | GLP1RKCNH2MCHR1HTR1ADRD2 | |
| SCHEMBL2884088 | 0.90 | MCHR1 (0.43) | GLP1RKCNH2MCHR1HTR1ADRD2 | |
| SCHEMBL2878480 | 0.82 | MCHR1 (0.46) | KCNH2MCHR1DRD2 | |
| SCHEMBL2878478 | 0.82 | MCHR1 (0.46) | KCNH2MCHR1DRD2 | |
| SCHEMBL2877692 | 0.81 | MCHR1 (0.45) | KCNH2MCHR1DRD2DRD4 | |
| SCHEMBL2877695 | 0.81 | MCHR1 (0.45) | KCNH2MCHR1DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL2894858 | 0.79 | MCHR1 (0.40) | KCNH2MCHR1DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL2894863 | 0.79 | MCHR1 (0.40) | KCNH2MCHR1DRD2DRD4 | |
| SCHEMBL2893041 | 0.78 | MCHR1 (0.39) | KCNH2MCHR1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MSD K.K. (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MC1R, MCHR1, MCHR2 | GLP1R 136/4885KCNH2 565/4885MCHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.